

Resource Summary Report

Generated by RRID on Aug 9, 2026

ClinicalStudyDataRequest.com (CSDR)

RRID:SCR_015512

Type: Tool

Proper Citation

ClinicalStudyDataRequest.com (CSDR) (RRID:SCR_015512)

Resource Information

URL: <https://clinicalstudydatarequest.com/Default.aspx>

Proper Citation: ClinicalStudyDataRequest.com (CSDR) (RRID:SCR_015512)

Description: Consortium of clinical study data providers. Its aim is to help the data sharing community drive scientific progress and improve medical care by facilitating access to patient-level data from clinical studies.

Abbreviations: CSDR

Synonyms: ClinicalStudyDataRequest, Clinical Study Data Request, ClinicalStudyDataRequest.com

Resource Type: data or information resource, portal, organization portal, consortium

Keywords: clinical study, data-sharing, patient-level data, study sponsor

Availability: The research community can contribute to this resource, Freely Available

Resource Name: ClinicalStudyDataRequest.com (CSDR)

Resource ID: SCR_015512

Record Creation Time: 20220129T080326+0000

Record Last Update: 20260808T190024+0000

Ratings and Alerts

No rating or validation information has been found for ClinicalStudyDataRequest.com (CSDR).

No alerts have been found for ClinicalStudyDataRequest.com (CSDR).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Okada M, et al. (2026) IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer. *Cancer science*, 117(3), 749.

Chi KN, et al. (2024) Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. *European urology*, 85(4), 382.

Furugaki K, et al. (2024) Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. *Molecular oncology*.

Gravas S, et al. (2024) Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression. *Prostate cancer and prostatic diseases*, 27(3), 469.

Furugaki K, et al. (2023) FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. *NPJ precision oncology*, 7(1), 107.

Kenmotsu H, et al. (2022) Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010). *Cancer science*, 113(12), 4327.

Blanco JR, et al. (2020) Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2). *PloS one*, 15(1), e0226724.

Ramachandran I, et al. (2019) Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. *Journal for immunotherapy of cancer*, 7(1), 276.

Small CB, et al. (2017) HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. *BMC infectious diseases*, 17(1), 256.